Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
7.89(c) 7.88(c) 7.2(c) 6.88(c) 6.72 Last
587 012 604 382 2 992 658 1 308 979 255 239 Volume
-2.47% -0.13% -8.63% -4.44% -2.33% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -99,0 M - -
Net cash position 2021 230 M - -
P/E ratio 2021 -2,59x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -120 M - -
Net cash position 2022 73,4 M - -
P/E ratio 2022 -2,24x
Yield 2022 -
Capitalization 263 M 263 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 150
Free-Float 96,3%
More Financials
Company
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). It is... 
Sector
Biotechnology & Medical Research
Calendar
10/22 | 08:00am
More about the company
Ratings of TCR2 Therapeutics Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about TCR2 THERAPEUTICS INC.
10/21TCR2 THERAPEUTICS : Wedbush Trims Price Target for TCR2 Therapeutics to $10 From $11, Main..
MT
10/21TCR2 THERAPEUTICS : SVB Leerink Downgrades TCR2 Therapeutics to Market Perform from Outper..
MT
10/21TCR2 THERAPEUTICS : Tcr-2 therapeutics reviews pipeline and strategy at r&d day
AQ
10/20TCR2 THERAPEUTICS : Press release issued by TCR2 Therapeutics Inc. on October 20, 2021 - F..
PU
10/20TCR2 THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and ..
AQ
10/20TCR2 THERAPEUTICS : TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
AQ
10/20TCR2 Therapeutics Inc. Reviews Pipeline and Strategy At R&D Day
CI
10/14TCR2 THERAPEUTICS : Tcr-2 therapeutics to host r&d day on october 20, 2021
AQ
10/13TCR2 THERAPEUTICS : TCR² Therapeutics to Host R&D Day on October 20, 2021
AQ
10/06TCR2 THERAPEUTICS : Tcr-2 therapeutics presents preclinical data on il-15 enhanced trucs a..
AQ
10/05TCR2 THERAPEUTICS : TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at..
AQ
10/05TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Spe..
CI
09/20TCR2 THERAPEUTICS : HC Wainwright Adjusts TCR2 Therapeutics' Price Target to $25 from $37,..
MT
09/20TCR2 THERAPEUTICS : Tcr-2 therapeutics announces positive interim results from ongoing pha..
AQ
09/20TCR2 THERAPEUTICS : Truist Securities Adjusts Price Target on TCR2 Therapeutics to $29 Fro..
MT
More news
News in other languages on TCR2 THERAPEUTICS INC.
09/17Selon Wedbush, la thérapie TCR2 doit organiser des essais supplémentaires pour le trait..
09/17Les produits thérapeutiques TCR2 chutent après les résultats provisoires de l'essai de ..
09/17TCR2 Therapeutics annonce les résultats provisoires de l'essai de phase 1/2 sur le Gavo..
09/02TCR2 Therapeutics reçoit la désignation de médicament orphelin de la FDA pour Gavo-Cel ..
More news
Analyst Recommendations on TCR2 THERAPEUTICS INC.
More recommendations
Chart TCR2 THERAPEUTICS INC.
Duration : Period :
TCR2 Therapeutics Inc. Technical Analysis Chart | TCRR | US87808K1060 | MarketScreener
Technical analysis trends TCR2 THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 6,88 $
Average target price 24,89 $
Spread / Average Target 262%
EPS Revisions
Managers and Directors
Garry E. Menzel President, Chief Executive Officer & Director
Mayur Ian Somaiya Chief Financial Officer
Ansbert K. Gadicke Chairman
Robert Hofmeister Chief Scientific Officer
Alfonso Quintás-Cardama Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TCR2 THERAPEUTICS INC.-77.76%263
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233